Bioconjugates

The ACS GCI Pharmaceutical Roundtable Bioconjugates Focus Team is dedicated to advancing sustainable strategies for the design, synthesis, and manufacture of conjugated therapeutic modalities over the next two decades. Our mission is to develop inherently stable conjugation systems that minimize hazardous reagents, implement site-specific chemistries to reduce heterogeneity, and create homogeneous bioconjugates for predictable performance and streamlined regulatory processes. By aligning sustainability goals with regulatory expectations, adopting recyclable components, and integrating reagent recovery and advanced filtration technologies, we aim to reduce waste, improve efficiency, and lower environmental impact. Through innovative approaches—such as enabling high-concentration formulations and designing next-generation bioconjugates for improved efficacy and reduced dosing—we seek to position bioconjugate development as a model for green, efficient pharmaceutical innovation where molecular design and sustainability are intrinsically linked.

Co-leads:

Raymond Sarksian, Ph.D – Amgen

Mike Kopach, Ph.D – Lilly